Data shows Cladribine benefits persist in RRMS patients
Data shows Cladribine benefits persist in RRMS patients
The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a study presented at the 68th American Academy of Neurology Annual Meeting...Read More - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 2 Replies
- 1551 Views
-
Last post by NHE
-
- 0 Replies
- 1664 Views
-
Last post by NHE
-
- 0 Replies
- 687 Views
-
Last post by DIM
-
- 0 Replies
- 2408 Views
-
Last post by NHE
-
- 0 Replies
- 1511 Views
-
Last post by frodo
-
- 0 Replies
- 1505 Views
-
Last post by NHE
-
- 0 Replies
- 2282 Views
-
Last post by frodo
-
- 5 Replies
- 13718 Views
-
Last post by gibbledygook